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The flavivirus West Nile virus (WNV) has spread rap-
idly throughout the world in recent years causing fever,
meningitis, encephalitis, and fatalities. Because the vi-
ral protease NS2B/NS3 is essential for replication, it is
attracting attention as a potential therapeutic target,
although there are currently no antiviral inhibitors for
any flavivirus. This paper focuses on elucidating inter-
actions between a hexapeptide substrate (Ac-KPGLKR-
p-nitroanilide) and residues at S1 and S2 in the active
site of WNV protease by comparing the catalytic activi-
ties of selected mutant recombinant proteases in vitro.
Homology modeling enabled the predictions of key mu-
tations in WNV NS3 protease at S1 (V115A/F, D129A/
E/N, S135A, Y150A/F, S160A, and S163A) and S2 (N152A)
that might influence substrate recognition and cata-
lytic efficiency. Key conclusions are that the substrate
P1 Arg strongly interacts with S1 residues Asp-129,
Tyr-150, and Ser-163 and, to a lesser extent, Ser-160,
and P2 Lys makes an essential interaction with Asn-
152 at S2. The inferred substrate-enzyme interactions
provide a basis for rational protease inhibitor design
and optimization. High sequence conservation within
flavivirus proteases means that this study may also be
relevant to design of protease inhibitors for other
flavivirus proteases.
West Nile virus (WNV)1 is a member of the Flavivirus
genus and is transmitted by mosquitoes, primarily Culex
species (1), between avian reservoir hosts and vertebrate
dead-end hosts including humans and horses. Many viruses
within this genus are medically important pathogens, includ-
ing dengue, Japanese encephalitis, tick-borne encephalitis,
and yellow fever viruses. WNV was first isolated in 1937 in
Uganda’s West Nile province and was subsequently found in
regions of Africa, the Middle East, Europe, Russia, South-
western Asia, and Australia (less severe subtype, Kunjin) (2).
Human infection is generally asymptomatic or causes a mild
febrile disease, West Nile fever (1). However, in a small
number of cases, predominantly in the elderly, the infection
with WNV results in encephalitis or meningitis that can be
fatal (1). Over the last decade, there has been an increase in
the frequency of human outbreaks and severity of disease
with recent epidemics in Israel (1998), Romania (1999),
Russia (1999), and New York (1999) (3). Since the introduc-
tion of WNV into New York in 1999, it has spread rapidly
throughout the United States (4,156 infections and 284
deaths in 44 states in 2002, 9862 infections and 264 deaths in
2003) (reported in 2000 by the CDC, Division of Vector-Borne
Infectious Disease: West Nile Virus, Center for Disease Con-
trol and Prevention, www.cdc.gov/ncidod/dvbid/westnile/
index.htm), Canada, and Mexico and has recently appeared in
the United Kingdom (5). There is currently no vaccine or anti-
viral treatment available for human WNV infection. However, a
chimeric live vaccine is in clinical trials and a veterinary vaccine
is licensed for use in equines and exotic zoo birds (6).
Flaviviruses are small enveloped viruses containing a sin-
gle-stranded positive sense RNA genome of 10–11 kb with a
single large open reading frame encoding a polyprotein pre-
cursor of 3400 amino acids. Gene expression requires both
host and a virally encoded protease to process the polyprotein
precursor into the individual functional proteins. They com-
prise three structural proteins (C, prM, and E) and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) (7). The viral protease encoded within the
N-terminal third of NS3 is responsible for cleavage at the
NS2A/NS2B, NS2B/NS3, NS3/NS4A, and NS4B/NS5 gene
junctions and also at a site near the C terminus of the C
protein to promote efficient generation of prM (Fig. 1) (8, 9).
Mutation of residues at any of these cleavage sites in the
related yellow fever virus was shown to prevent efficient
cleavage and abolished virus infectivity in cell culture (10–
13), highlighting a vital role for the NS3 protease in replica-
tion. The essential nature of this protease in the virus life
cycle is the basis for interest in NS3 as a possible target for
developing antiviral inhibitors.
NS3 is a multifunctional protein in which the N-terminal 184
amino acids encode for the protease and the C-terminal region
encodes a nucleotide triphosphatase, an RNA triphosphatase,
and a helicase (14–16). The NS3 protease is a trypsin-like
serine protease with a classic catalytic triad (His-51, Asp-75,
and Ser-135) (17). Protease activity has been shown for a
number of related flaviviruses to be dependent on the asso-
ciation of NS2B as a cofactor (18). A central 40 amino acid
hydrophilic domain within the largely hydrophobic NS2B
protein has been shown to be sufficient for cofactor activity
(19, 20). The flanking hydrophobic domains within NS2B are
likely to function in promoting membrane association of
NS2B-NS3 (21, 22). NS2B-NS3pro has high specificity for
substrate processing requiring a dibasic recognition sequence
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(P2-Lys, P1-Arg) that is conserved throughout the flaviruses
(7). This relatively unusual substrate specificity suggests
that inhibitors could be somewhat selective over most host
serine proteases (19).
Fundamental to the design of a specific inhibitor is a detailed
understanding of the interactions between protease residues in
the active site and substrates. The structure of the WNV NS3
protease is unknown, but there are reported crystal structures
for related NS3 proteases of hepatitis C virus (HCV) with a
cofactor (23) and Dengue-2 virus without NS2B cofactor (24).
Therefore, the latter structure was of an inactive enzyme. In
this study, a homology-modeled structure of the WNV NS3
protease, created through sequence comparison with the HCV
and Dengue-2 virus NS3 protease structures, was used to pre-
dict residues in the S1 and S2 binding pockets that probably
make important interactions with substrate residues (25).
Identified residues were then mutated in a recombinant cata-
lytically active construct by site-directed mutagenesis, and ki-
netic parameters for the mutant WNV proteases were deter-
mined and compared.
EXPERIMENTAL PROCEDURES
General Methods—Protected amino acids and resins were obtained
from Auspep, Novabiochem, and PepChem. Trifluoroacetic acid, piper-
idine, N,N-diisopropylethylamine, dichloromethane, and N,N-dimeth-
ylformamide (peptide synthesis grade) were purchased from Auspep.
All of the other materials were of reagent grade unless otherwise stated.
Crude peptides were purified by reversed-phase high pressure liquid
chromatography on a Vydac C18 column (10–15 m, 300 Å, 50  250
mm) using a gradient mixture of solvent (A) 0.1% trifluoroacetic acid/
water and (B) 0.1% trifluoroacetic acid/10% water/90% acetonitrile.
Analytical reversed-phase high pressure liquid chromatography was
performed on a Waters system equipped with a 717 plus autosampler,
660 controller, and a 996 photodiode array detector using a reversed-
phase Phenomenex Luna C18 column (5 m, 100 Å, 250  4.6 mm).
Purified peptides were characterized by analytical reversed-phase high
pressure liquid chromatography (linear gradient 0–100% B over 30
min), mass spectrometry, and 1H NMR spectroscopy. The molecular
mass of the peptides was determined by electrospray mass spectrome-
try on a Micromass LCT mass spectrometer. 1H NMR spectra were
recorded on samples containing 4 mM peptide in Me2SO-d6 (550 l) on
a Bruker Avance 600 spectrometer at 298 K. Proton assignments were
determined by TOCSY (80 ms of mixing time), DQF-COSY, ECOSY,
and NOESY (350 ms of mixing time) spectra using the sequential
assignment method (26). All of the spectra were processed on Silicon
Graphics R10000 or R12000 workstations using XWINNMR, version
2.6 (27).
Homology Modeling—West Nile virus NS3 protease homology mod-
els were generated using the structures of Dengue-2 virus NS3 protease
without cofactor (Protein Data Bank 1BEF) (24) and with Bowman-Birk
inhibitor (Protein Data Bank 1DF9, subunit B) (29) and hepatitis C
virus NS3 protease with bound cofactor (Protein Data Bank 1A1Q) (23).
Models were generated using the Modeler and Homology modules
within InsightII (31) on a Silicon Graphics R10000 workstation. Se-
quences were aligned using Align 2D, Structure Alignment (Homology
module, InsightII), and ClustalW alignment (32). Secondary structure
predictions were conducted using the web-based PsiPred prediction for
each of the three NS3 protease sequences (33). Electrostatic potential
mapping was performed on the WNV NS3 protease model using the
Delphi module in InsightII (34). A four residue P3-P1 substrate based
on the NS4B-NS5 cleavage site (Leu-Lys-Arg-Gly) was docked into the
active site of a homology model of the WNV NS3 protease using GOLD,
version 2.1 (35). A specified distance constraint between the substrate
residue Arg (P1) and WNV protease Tyr-150 (S1) was used based on our
FIG. 1. Flavivirus polyprotein processing and site-directed mutagenesis constructs. A, the upper schematic shows sites cleaved by host
proteases (shaded arrows) and the virus-encoded NS2B/NS3 protease (open arrows). The proteolytic domain of NS3 and the NS2B cofactor are
shaded. The schematic below shows this region expanded and the recombinant construct used in this study. Features of the NS2B.NS3pro complex
include the cleavage site (open arrow), the catalytic triad (asterisks), the hydrophobic domains of NS2B (solid boxes), and the minimum 40 residue
cofactor domain required for catalytic activity. The construct CF40.Gly.NS3pro comprises this essential 40 residue domain of NS2B linked to the
NS3 protease domain by a flexible glycine linker (Gly4/Ser/Gly4). B, sequence of the wild type WNV NS3 between residues 111 and 170 (top
sequence) and the residues mutated in this study. The boxes highlight residues homologous to those originally predicted by Bazan and Fletterick
(17) to line the substrate-binding cleft.
Mutagenesis of Recombinant WNV NS3 Protease 2897
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
understanding of protease-inhibitor interactions (36, 37).2 Docked
structures were ranked for best-fitting conformations using GOLD,
version 2.1 (35).
Plasmid Construction—The expression plasmid pQE9 WNV
CF40.Gly.NS3pro generated previously (25) from WNV (strain NY99–
4132) was used as a template for generating site-directed mutant con-
structs. Mutations (V115A, V115F, D129A, D129E, D129N, S135A,
Y150A, Y150F, N152A, S160A, and S163A) in WNV NS3 were made
using overlapping PCR. In the first round of PCR, two separate PCR
reactions were performed with the primer pairs WNV
CF40aa.FBamHI/WNV Mutation.R and WNV Mutation.F/WNV
NS3pro.RHindIII to amplify products flanked by overlapping sequences
incorporating the site-directed mutation. Table I shows the primer
sequences. These products were then joined in the second round of PCR
using the outer primers WNV CF40aa.FBamHI and WNV
NS3pro.RHindIII. The resulting PCR products were digested with
BamHI and HindIII and cloned into pQE9. The incorporation of the
desired mutations was confirmed by automated sequence analysis.
Enzyme Expression and Purification—The pQE9 vector was used for
high level inducible expression of N-terminal hexahistidine-tagged re-
combinant proteins. Cultures of the Escherichia coli strain SG13009
transformed with the expression plasmid were grown in 500 ml of LB
medium containing 100 g/ml ampicillin and 25 g/ml kanamycin at
37 °C until the A600 nm reached 0.5. The expression of the recombinant
protein was induced by the addition of isopropyl--D-thiogalactopyr-
anose to a final concentration of 0.3 mM and incubated for an additional
3 h at 22 °C. Cells were harvested by centrifugation and stored at
20 °C.
For protein purification, cell pellets were thawed, resuspended in
lysis buffer (5 ml/g wet pellet, 50 mM HEPES, pH 7.5, 300 mM NaCl, 10
mM imidazole, 5% glycerol) and protease inhibitors were added (1 g/ml
aprotinin, 1 g/ml leupeptin, 1 g/ml benzamide, 1 mM phenylmethyl-
sulfonyl fluoride, 10 g/ml TCLK, all final concentrations) in an at-
tempt to minimize proteolytic cleavage of recombinant protein. Subse-
quent analyses have found that these standard serine protease
inhibitors do not inhibit WNV CF40.Gly.NS3pro (25). Resuspended
cells were lysed by three passages through a French press (1000 Pas-
cals) and then centrifuged (27,000  g, 20 min, 4 °C).
The recombinant proteases, each with a N-terminal hexahistidine
tag, were purified by affinity chromatography on a Ni2-nitrilotriacetic
acid-agarose 1-cm column (Qiagen) that had been preequilibrated (50
mM HEPES buffer (30 ml), pH 7.5, 300 mM NaCl, 10 mM imidazole, 5%
glycerol). Resin was then removed, mixed with the supernatant fraction
of cell lysates, and incubated at 4 °C on a rotator for 30 min to allow the
His-tagged protein to bind to the Ni2 resin. The column was repacked
and washed with 30 ml of buffer containing 20 mM imidazole, and the
proteins were eluted into 6  1-ml fractions with buffer containing 100
mM imidazole. The pre- and post-isopropyl--D-thiogalactopyranose in-
duction samples, soluble and insoluble fractions, and the elution frac-
tions were analyzed by 12% SDS-PAGE.
Substrate—The pNA substrate corresponding to the native WNV
NS3 protease cleavage site Ac-KPGLKR-pNA (NS4A-NS5) was synthe-
sized by a previously reported method (39) (Ac-KPGLKR-pNA, Rt 
16.9 min). Electrospray mass spectrometry was [M  H]  860.7 and
[M  2H]/2  430.8. The NMR spectral data are as follows: 1H NMR
(Me2SO-d6)  10.58 (s, 1H, pNA-NH); 8.23 (d, 2H, pNA-ArH); 8.19 (t,
1H, GlyNH); 8.18 (d, 1H, ArgNH); 8.05 (d, 1H, Lys-1NH); 7.95 (d,
1H, Lys-5NH); 7.84 (d, 2H, pNA-ArH); 7.76 (d, 1H, LeuNH); 7.68 (m,
6H, 2 LyszNH3); 7.7–6.5 (4H, m, 2 ArgNH2); 7.61 (t, 1H, Arg-6NH);
4.47 (m, 1H, Lys-1CH); 4.36 (m, 1H, ArgCH); 4.30 (m, 1H, LeuCH);
4.26 (m, 1H, ProCH); 4.24 (m, 1H, Lys-5CH); 3.68 (m, 2H, GlyCH2);
3.67 (m, 1H, ProCH); 3.56 (m, 1H, ProCH); 3.11 (m, 2H, ArgCH2);
2.75 (m, 2H, Lys1CH2); 2.73 (m, 2H, Lys-5CH2); 2.05 (m, 1H,
ProCH); 1.93 (m, 1H, ProCH); 1.85 (m, 1H, ProCH); 1.82 (s, 3H,
Ac-CH3); 1.80 (m, 1H, ProCH); 1.75 (m, 1H, ArgCH); 1.66 (m, 1H,
Lys-5CH); 1.65 (m, 1H, ArgCH); 1.63 (m, 1H, Lys-1CH); 1.56 (m,
1H, Lys-5CH); 1.56 (m, 1H, ArgCH); 1.56 (m, 1H, LeuCH); 1.53 (m,
1H, LysCH); 1.51 (m, 2H, Lys-1CH2); 1.50 (m, 2H, Lys-5CH2); 1.49
(m, 1H, Lys-1CH); 1.49 (m, 1H, Lys-1CH); 1.48 (m, 1H, LeuCH);
1.47 (m, 1H, ArgCH); 1.43 (m, 1H, LeuCH); 1.32 (m, 1H, Lys-1CH);
1.32 (m, 1H, Lys-5CH); 0.87 (d, 3H, LeuCH3); and 0.83 (d, 3H,
LeuCH3). High resolution electrospray mass spectrometry was calcu-
lated for C39H65N13O9 ([M  H]
  860.5101, found 860.5061; [M 
2H]/2  430.7587, found 430.7617).
Enzyme Kinetics—The recombinant WNV protease (WNV
CF40.Gly.NS3pro) and site-directed mutants (V115A, V115F, D129A,
D129E, D129N, S135A, Y150A, Y150F, N152A, S160A, and S163A)
were assayed against a hexapeptide substrate corresponding to P6-P1
of the known endogenous cleavage site NS4B-NS5 (Ac-KPGLKR-pNA)
with a chromogenic pNA group in the P1 position. The cleavage of the
pNA chromophore from the peptide substrate by the WNV proteases
produced a detectable color change at 405 nm, allowing protease activ-
ity to be measured. The assay was conducted in a 96-well plate with a
final reaction volume of 200 l containing 0.5 M recombinant protease
and 1 mM Ac-KPGLKR-pNA and with optimal processing conditions
described by Nall et al. (25) consisting of a final concentration of 50 mM
Tris, pH 9.5, 30% glycerol, 1 mM CHAPS. After preincubation of buff-
ered protease and substrate in separate wells (10 min, 37 °C), catalysis
was initiated by mixing substrate with enzyme-buffer solution by au-
tomatic shaking. The optical density was measured at 405 nm every
30 s for 10 min in a SpectraMax 250 reader, and the average change in
millioptical density/min was calculated. Assays were carried out in
triplicate, and a control assay containing no enzyme was also con-
ducted. Those proteases that were found to possess significant activity
(greater than the negative control) were re-assayed in triplicate against
2 Tyndall, J. D. A., Nall, T., and Fairlie, D. P. (2005) Chem. Rev., in
press.
TABLE I
Primers used for construction of WNV CF40.Gly.NS3pro and site-directed mutants
Primer Sequence
WNV CF40aa.F (BamHI) 5-CGATGACGGCGGATCCACAGATATGTGGA TTGAGAGAACG-3
WNV NS3pro.R (HindIII) 5-GCCCCCAAGCTTACAGCATCTCAGGTTCGAAT-3
WNV NS3_V115A.F 5-ACGAAACCAGGAGCGTTCAAAACACCT-3
WNV NS3_V115A.R 5-AGGTGTTTTGAACGCTCCTGGTTTCGT-3
WNV NS3_V115F.F 5-ACGAAACCAGGGTTCTTCAAAACACCT-3
WNV NS3_V115F.R 5-AGGTGTTTTGAAGAACCCTGGTTTCGT-3
WNV NS3_D129A.F 5-CCGTGACTTTGGCATTCCCCACTGGAA-3
WNV NS3_D129A.R 5-TTCCAGTGGGGAATGCCAAAGTCACGG-3
WNV NS3_D129E.F 5-GCCGTGACTTTGGAGTTCCCCACTGGA-3
WNV NS3_D129E.R 5-TCCAGTGGGGAACTCCAAAGTCACGGC-3
WNV NS3_D129N.F 5-GCCGTGACTTTGAACTTCCCCACTGGA-3
WNV NS3_D129N.R 5-TCCAGTGGGGAAGTTCAAAGTCACGGC-3
WNV NS3_S135A.F 5-CCCATCGGAACAGCAGGCTCACCAATA-3
WNV NS3_S135A.R 5-TATTGGTGAGCCTGCTGTTCCAGTGGG-3
WNV NS3_Y150A.F 5-GTGATTGGACTGGCTGGCAATGGAGTC-3
WNV NS3_Y150A.R 5-GACTCCATTGCCAGCCAGTCCAATCAC-3
WNV NS3_Y150F.F 5-GTGATTGGACTGTTTGGCAATGGAGTC-3
WNV NS3_Y150F.R 5-GACTCCATTGCCAAACAGTCCAATCAC-3
WNV NS3_N152A.F 5-GGGCTTTATGGAGCTGGAGTCATAATG-3
WNV NS3_N152A.R 5-CATTATGACTCCAGCTCCATAAAGCCC-3
WNV NS3_S160A.F 5-ATGCCCAACGGAGCATACATAAGTGCG-3
WNV NS3_S160A.R 5-CGCACTTATGTATGCTCCGTTGGGCAT-3
WNV NS3_S163A.F 5-GGCTCATACATAGCAGCGATAGTGCAG-3
WNV NS3_S163A.R 5-CTGCACTATCGCTGCTATGTATGAGCC-3
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eight different substrate concentrations ranging from 62.5 M to 1 mM
for determination of kinetic constants. To obtain accurate kinetic data
for the D129A site-directed mutant, which possessed only slightly
higher activity than the negative control, it was assayed in quadrupli-
cate at the higher enzyme concentration of 2.5 M and eight higher
substrate concentrations ranging from 125 M to 2 mM.
Kinetic parameters were calculated from weighted non-linear regres-
sion of the initial velocities as a function of the eight substrate concen-
trations using GraphPad Prism 4 software. The kcat/Km values were
calculated assuming that Michaelis-Menten kinetics v  Vmax[S]/([S] 
Km). Triplicate measurements were taken for each data point. The data
are reported as the means  S.E.
RESULTS
Protease Architecture and Design of Mutant Proteases—A
structural homology model of the WNV NS3pro (25) was recon-
structed here based on the sequence alignments and the crystal
structures of Dengue-2 virus NS3pro in complex with a Bow-
man-Birk inhibitor (29) and of HCV NS3pro in complex with its
cofactor NS4A (Fig. 2) (28). The HCV NS3pro structure was
included to enable the modeling of the WNV NS3pro in the
context of its NS2B cofactor.
The electrostatic surface map of WNV NS3pro is shown in
Fig. 2A, highlighting acidic (red), basic (blue), and hydrophobic
(white) regions with a previously reported substrate (P3-P1
section, Leu-Lys-Arg-Gly corresponding to the WNV NS4B/
NS5 cleavage site) docked in the active site. Based on homology
with HCV NS3pro, the cofactor threads through the protease
with the basic region in the upper left quadrant of Fig. 2A
showing one end of the putative cofactor-binding domain. The
substrate-binding active site is located in or on a largely hy-
drophobic region of the enzyme flanked by two acidic regions at
Asp-129 and Asp-75 (shown in Fig. 2B). The model revealed
that the S1 site was the largest pocket, that the S2 and subsites
beyond were very shallow, and that the substrate must spread-
eagle itself on the surface of the protease (Fig. 2B). Residues
Val-115, Asp-129, Tyr-150, Ser-160, and Ser-163 are predicted
to line the enzyme S1 subsite, whereas Asn-152 is predicted to
be a key residue in the S2 subsite (Fig. 2, C and D), and these
were chosen for site-directed mutagenesis. The S1 pocket was
the major focus of our mutagenesis study as it appears to be the
most promising site for targeting with a competitive inhibitor.
Tyr-150 and Ser-163 are analogous to residues in the S1
subsite of the Dengue-2 virus NS3 protease that have been
suggested to interact with P1 substituents of its substrate (24,
29), and Tyr-150 has been identified by mutagenesis as impor-
tant for the activity of Dengue-2 virus protease activity (38).
Therefore, we decided to make the corresponding Y150A and
Y150F mutant WNV NS3 proteases to test whether a -cation
interaction with the P1 Arg is crucial for substrate recognition
FIG. 2.WNVNS3pro homologymodel. A, electrostatic surface map highlighting acidic (red), basic (blue), and hydrophobic (white) regions with
a bound substrate (P3-P1 segment, Leu-Lys-Arg-Gly) shown in green (stick model). B, enlarged view of the substrate bound in the protease active
site. Two acidic residues, the catalytic Asp-75 as well as Asp-129 at the rim of the deep P1 binding pocket (S1 subsite), are highlighted. The P3 to
P1 residues are also identified. C,magnified region of substrate binding groove (substrate in gold) showing putative substrate-interacting residues
in the S1 (Val-115, Asp-129, Tyr-150, Ser-160, and Ser-163) and S2 (Asn-152) subsites that were targeted for site-directed mutagenesis. D,
substrate-WNV protease interactions (substrate in gold and protease in blue). Catalytic Ser-135 residue is displayed in bold and denoted with an
asterisk. Protease substrate regions are shown in boldface (S1, S2, and S1) along with residues predicted by the model to interact with
the substrate.
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and processing. The S160A and S163A mutants were made to
test the possible hydrogen-bonding interaction of these resi-
dues in S1 with Arg at P1 of the substrate.
Asp-129 is highly conserved among the flaviviruses and cor-
responds to Asp-189 of trypsin, a critical residue that sits at the
base of the substrate binding pocket and forms an electrostatic
bond with the P1 Lys or Arg of the trypsin cleavage site (30).
However, as noted above, Tyr-150 takes up this position in the
flavivirus NS3 protease with Asp-129 located more peripher-
ally at the outer edge of the S1 site (see Fig. 2A). Despite its
high level of conservation across the flaviviruses, previous cell-
based mutagenesis studies appeared to show that Asp-129
could be relatively freely substituted with retention of signifi-
cant activity (38). In addition, crystallographic data for the
Dengue-2 virus NS3 suggest that Asp-129 does not appear to
interact with the P1 Lys but to only interact with a P1 Arg in
one of two conformations (29). We decided to test more accu-
rately the importance of Asp-129 for substrate processing by
making three mutant WNV CF40.Gly.NS3pro enzyme con-
structs (D129A, D129E, and D129N). Conservative mutants
D129E (no change in charge) and D129N (isosteric replacement
but loss of charge) together with D129A (loss of charge and
bulk) at S1 would clarify whether a charged group is important
for interaction with Arg at P1 of the substrate. The mutations
of V115F and V115A were made to clarify the importance of
Tyr-150 and determine the actual size of the S1 pocket. The
rationale behind these two mutations was that V115F could fill
the space available for the binding of a basic residue while
being complimentary to the existing Tyr-150. V115A was de-
signed to ascertain the importance of valine versus the size of
the cavity.
Because of the known dibasic P1/P2 substrate specificity of
WNV NS3 protease, we also wanted to make the mutations at
the S2 site in the enzyme. The inspection of the homology
structure suggested that Asn-152 was most likely to hydrogen
bond to the basic P2 Lys residue of the substrate, so we chose
the N152A mutation to test this effect. An inactive protease
was constructed by mutation of the catalytic serine 135 to
alanine as a negative control.
Comparative kinetic studies of these mutant proteases and the
assessment of the role of the mutated residues in substrate bind-
ing were expected to validate the predictions made from the
homology structure regarding enzyme-substrate interactions.
Expression and Purification of WNV CF40.Gly.NS3pro and
Mutants—The recombinant WNV protease (WNV CF40.Gly.
NS3pro) used in this study comprises the essential 40 amino
acid cofactor domain of NS2B joined to the 184 amino acid
protease domain of NS3 by a flexible nonapeptide G4SG4, ab-
breviated as WNV CF40.Gly.NS3pro (25). This construct was
cloned into the pQE9 expression vector and used to transform
E. coli strain SG13009 competent cells. The soluble recombi-
nant WNV CF40.Gly.NS3pro was purified by Ni2 affinity
chromatography and was shown to be catalytically active
against peptide substrates based on the known cleavage sites of
WNV NS3pro (25).
The mutations (Fig. 1B) were incorporated into the WNV
CF40.Gly.NS3pro construct by overlapping PCR and the mu-
tant constructs cloned into the pQE9 expression plasmid. Mu-
tagenesis and cloning into pQE9 were confirmed by automated
sequence analysis. Fig. 3 shows SDS-PAGE profiles of the
WNV CF40.Gly.NS3pro and site-directed mutant recombi-
nants after purification by Ni2 affinity chromatography. The
major species present for all of the mutants displays a band at
32 kDa and was attributed to the catalytically active recombi-
nant protease. Two additional bands at 22 and 20 kDa corre-
spond to the products of autocatalytic cleavage, because they
were not present in the purification of the inactive catalytic
S135A mutant protease. However, these products were de-
tected in the purified WNV CF40.Gly.NS3pro recombinant and
mutant recombinants V115A, D129A, D129E, D129N, Y150F,
and S160A. Therefore, the relative levels of these cleavage
products in the constructs may give an indication of catalytic
activity and suggest that the single amino acid mutants V115A,
D129A, D129E, D129N, Y150F, and S160A are active to vary-
ing degrees, whereas the mutants S135A, V115F, Y150A,
N152A, and S163A are inactive or close to inactive.
Catalytic Activity of Recombinant WNV CF40.Gly.NS3pro
and Mutants—To accurately investigate the relative activities
of the WNV CF40.Gly.NS3pro and site-directed mutants, pu-
rified recombinant enzymes were assayed in vitro against the
chromogenic substrate Ac-KPGLKR-pNA based on the known
P6-P1 sequence of the WNV NS4B/NS5 junction. Initially, a
single substrate concentration of 1 mM was used and the assays
were conducted in triplicate. Fig. 4 shows the relative substrate
cleavage velocity of the site-directed mutant recombinants
compared with the wild type WNV CF40.Gly.NS3pro and also
a control containing no enzyme.
The mutants V115A, D129A, D129E, D129N, Y150F, and
S160A were selected for further kinetic analyses against a
range of substrate concentrations. The mutants V115F, Y150A,
FIG. 3. Purified WNV CF40.Gly.NS3pro and single amino acid mutants. Recombinant proteases purified by Ni2 affinity chromatography
were examined by SDS-PAGE and Coomassie Blue staining. Gels showed a major band at around 32 kDa corresponding to the full-length
recombinant protein. Two minor low molecular weight proteins (MW) probably the products of autocatalytic cleavage, were present in WNV
CF40.Gly.NS3pro and mutants V115A, D129A, D129E, D129N, Y150F, and S160A.
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N152A, and S163A showed catalytic activity equal to that of
the negative control and the inactive catalytic S135A mutant.
These mutants were not analyzed further and were designated
as inactive.
Kinetic parameters for wild type WNV CF40.Gly.NS3pro
and those mutants with comparable or significant activity were
generated by assaying at eight different substrate concentra-
tions (62.5 M-1 mM). To obtain kinetic data for the D129A
recombinant protease, which showed only slightly higher ac-
tivity than the negative control, the assay was performed at a
higher enzyme concentration (2.5 M) against eight different
substrate concentrations (125 M-2 mM). Kinetic parameters
generated for WNV CF40.Gly.NS3pro and site-directed mu-
tants are shown in Table II.
The following comparisons between the kinetic parameters
were used to provide evidence for the role of the targeted
residues in substrate binding. The mutagenesis of V115A re-
tained a similar kcat value but produced a 2-fold decrease in
catalytic efficiency (kcat/Km) due to the loss of substrate affinity
(2-fold increase in Km). The mutagenesis of D129A produced an
extremely large decrease in catalytic efficiency (1500-fold de-
crease in kcat/Km) because of a 90-fold decrease in kcat and also
a large decrease in substrate affinity (17-fold increase in Km).
The conservative mutation D129E gave an unexpectedly large
decrease in catalytic efficiency (170-fold decrease in kcat/Km)
because of a 50-fold decrease in kcat and a decrease in substrate
affinity (3-fold increase in Km). The isosteric mutation D129N
performed better than D129A and D129E, resulting in a 90-fold
decrease in catalytic efficiency (kcat/Km) due to a 25-fold de-
crease in kcat and a decrease in substrate affinity (3.6-fold
increase in Km). The conservative mutation Y150F produced a
10-fold decrease in catalytic efficiency (kcat/Km) due to a 7-fold
decrease in kcat and a small decrease in substrate affinity
(1.4-fold increase in Km). Ser-160 showed a 5-fold decrease in
catalytic efficiency (kcat/Km) because of a 2.4-fold decrease in
kcat and a small decrease in substrate affinity (2.1-fold increase
in Km).
DISCUSSION
Correlation of Mutagenesis Results to Substrate Interac-
tions—The effect of site-directed mutagenesis on protease effi-
ciency is frequently used to provide evidence for the importance
of individual enzyme residues in substrate binding and proc-
essing. Focused mutagenesis of protease residues identified
from our homology structure and predicted to be important for
interactions with P1 and P2 residues of the dibasic substrate
proved to be quite revealing.
Tyrosine 150—Tyrosine 150 is conserved throughout flavivi-
rus NS3 proteases. It lies at the base of the S1 pocket in the
homology model of WNV NS3pro, just as observed in Dengue-2
virus NS3pro by crystallographic data (24, 29). The aromatic
ring of Tyr-150 is predicted to make a primary -cation inter-
action with the basic Arg residue at P1 of the substrate. Sub-
stitution of the Tyr-150 residue by alanine resulted in an inac-
tive enzyme, consistent with previous mutagenesis results for
Dengue-2 virus (38) and supporting the prediction that Tyr-150
makes a major interaction with the P1 residue.
The conservative mutation of Y150F that simply removes the
hydroxyl group from the aromatic ring did not substantially
alter catalytic activity but did cause a 10-fold reduction in
catalytic efficiency and a small decrease in substrate affinity
(1.4-fold increase in Km). This result supports the proposed
-cation interaction that requires only the aromatic ring of
both of these S1 residues. The decrease in catalytic efficiency
might be attributed to the removal of a hydrogen bond between
the tyrosine hydroxyl group and P1 of the substrate or alter-
natively (and more likely) to an increase in the energy of the
aromatic -orbitals.
Serine 163—Serine 163 is also conserved throughout the
flavivirus NS3 proteases. The homology model predicts Ser-163
to line the S1 pocket, and this residue has been suggested to
make an interaction with a P1 Arg in the crystal structure of
the Bowman-Birk inhibitor bound to Dengue-2 virus NS3pro
(29). Mutation of Ser-163 to alanine inactivated the protease,
confirming that Ser-163 makes a critical interaction with the
P1 Arg, presumably via a hydrogen bond from its hydroxyl
group.
Aspartate 129—Aspartate 129 is also conserved throughout
flavivirus NS3 proteases. Based on homology to trypsin, Asp-
129 (Asp-189 of trypsin) was originally believed to lie at the
FIG. 4. Relative catalytic activities of the recombinant pro-
teases. The wild type recombinant protease, site-directed mutant re-
combinants, and a control containing no protease were assayed in
triplicate against Ac-KPGLKR-pNA at a concentration of 1 mM. The bar
graph shows protease activity as a percentage of the wild type protease
activity (S.E.). Based on these data, it was considered that mutants
V115F, Y150A, N152A, and S163A were inactive or were of extremely
low activity because their activities were comparable to the negative
control and the inactive catalytic S135A mutant.
TABLE II
Kinetic parameters for substrate processing by mutants of
WNVCF40.Gly.NS3Pro
Assays were conducted in a final reaction volume of 200 l containing
50 mM Tris, pH 9.5, 30% glycerol, and 1 mM CHAPS. Wild type, V115A,
D129E, D129N, Y150F, and S160A were assayed in triplicate at an
enzyme concentration of 0.5 M and eight different Ac-KPGLKR-pNa
concentrations ranging from 62.5 M to 1 mM. D129A was assayed in
quadruplicate at the higher enzyme concentration of 2.5 M and eight
Ac-KPGLKR-pNa concentrations ranging from 125 M to 2 mM.
Km kcat kcat/Km
M s1 M1 s1
Wild type 170  14 0.965  0.026 5694  345
V115A 360  35 0.872  0.036 2420  141
D129A 2942  730 0.011  0.001 3.8  0.3
D129E 561  90 0.019  0.002 34  2.6
D129N 611  56 0.038  0.002 62  2.9
Y150F 246  17 0.133  0.004 541  26
S160A 357  29 0.394  0.014 1102  55
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base of the S1 pocket and make the primary charge stabiliza-
tion interaction with the substrate P1 arginine (17). However
crystallization of the Dengue-2 virus NS3pro and homology to
HCV NS3pro showed that Tyr-150 lies at the base of the S1
protease pocket. The extent of the substrate interaction sup-
plied by Asp-129 was also queried in earlier cell-based mu-
tagenesis studies, which showed that its substitution in Den-
gue-2 virus NS3 had a limited effect on protease activity (38).
In contrast to the cell-based findings (38), kinetic analysis in
this study revealed that the D129A mutation substantially
reduced protease activity in vitro. Thus, Asp-129 must provide
an important interaction with the substrate, presumably via a
salt bridge or hydrogen bond with the positive charge of the P1
Arg. Crystallographic data for Dengue-2 virus NS3pro with
Bowman-Birk inhibitor show that P1 Arg possibly exists in two
conformations, one where it is bound to Asp-129 and one where
it is bound to Tyr-150 and Ser-163 (29). If this is correct,
Asp-129 may play a role in the initial binding of the P1 Arg
before it translocates deeper into the S1 pocket where it can
subsequently bind to Tyr-150 and Ser-163 during cleavage. The
kinetic parameters generated for the D129A mutant are con-
sistent with this proposal, the large Km value (17-fold larger
than the wild type) suggesting that D129 is probably involved
in substrate binding.
The conservative substitution D129E resulted in a 170-fold
decrease in catalytic efficiency, a small decrease in substrate
affinity (3-fold increase in Km), and a large decrease in kcat.
Because binding affinity is only slightly decreased, the D129E
increase in side chain length must interfere in the catalytic
mechanism rather than retarding substrate binding. This
would suggest that binding to Tyr-150 and Ser-163 without
first interacting with Asp-129 positions the substrate differ-
ently, resulting in less efficient cleavage. Alternatively, if Asp-
129 provides an initial interaction that is involved in the trans-
location of the P1 Arg into the S1 pocket, the larger side chain
may not deliver the P1 Arg into its correct binding position with
Tyr-150 and Ser-163 but hold it in a different position, which
would result in inefficient cleavage.
The isosteric replacement D129N mutant also displayed de-
creased (90-fold) catalytic efficiency and a small decrease in
substrate affinity (3.6-fold increase in Km); however, this mu-
tant performed better than D129A or D129E. This isosteric
replacement of an acid side chain by an amide side chain seems
to support the notion that a hydrogen bond interaction is im-
portant between residue 129 and the P1 Arg of substrate, but
either is not as pronounced for Asn as Asp or is supplemented
by a salt bridge interaction as in the case of D129.
Interestingly, whereas the kinetic analysis of the Asp-129
mutants showed a dramatic decrease in protease efficiency, the
autocatalytic activity of Asp-129 mutants observed in this
study appears to be close to the wild type level (Fig. 4), similar
to an observation made (38) for autocatalysis by Dengue-2
virus NS2B-NS3pro D129 mutants. These findings may simply
be the consequence of cis-cleavage of the proximally juxtaposed
residues during protease expression. Alternatively, this com-
parison of different catalytic efficiencies may not be relevant
because the latter case involves autocatalytic cleavage of an
extended substrate, whereas the former case involves cleavage
of only a six-residue substrate. Intermolecular forces outside
the six-residue sequence may contribute to the association of
substrate and the protease active site.
If Asp-129 does provide an initial interaction with the P1 Arg
as suggested above, this may be exploited in the design of
improved inhibitors. By designing an inhibitor to make simul-
taneous interactions with Tyr-150, Ser-163, and Asp-129, the
binding affinity would be significantly greater than that of the
P1 Arg and therefore should provide a very effective competi-
tive inhibitor.
Asparagine 152—Asparagine 152 was shown by the homol-
ogy model of WNV NS3pro to line the S2 pocket and is likely to
make an interaction with the P2 lysine. The mutation of Asn-
152 to alanine inactivated the protease, supporting the predic-
tion that it provides an essential interaction with the P2 Lys
via a hydrogen bond. Consistent with the importance of inter-
actions with both P1 and P2 basic substrate residues, autocat-
alytic cleavage was not observed during purifications of any of
the mutant enzymes containing Y150A, S163A, or N152A.
Valine 115—The homology model suggested that valine 115
lines the S1 pocket. Val-115 was not expected to provide a
substrate interaction but was included in this mutagenesis
study to investigate the size of the S1 pocket. Replacing Val-
115 with the smaller alanine caused only a 2-fold decrease in
catalytic efficiency because of a decrease in substrate affinity
(2-fold increase in Km). This may be the result of a small
increase in the size of the S1 binding pocket for the occupying
P1 Arg side chain, which is less than optimal. Substitution of a
large phenylalanine residue for Val-115 inactivates the prote-
ase most probably because the S1 pocket becomes too small to
accommodate binding of the P1 Arg.
Serine 160—Serine 160 is not highly conserved in flavivirus
NS3 proteases, but the homology model of WNV NS3pro sug-
gested that Ser-160 may contribute an interaction to the P1
side chain. The S160A mutation resulted in a 5-fold decrease in
catalytic efficiency and a decrease in substrate affinity (2-fold
increase in Km), suggesting that Ser-160 may provide a weak
interaction with the substrate, possibly via a hydrogen bond.
This observation would represent a variation in substrate rec-
ognition between members of the NS3 protease family.
CONCLUSION
This study implicates some important requirements in the
WNV NS2B/NS3 protease for recognition of a prototype dibasic
substrate sequence. It has demonstrated that the enzyme res-
idues at both S1 and S2 pockets are essential for substrate
recognition and catalytic efficiency.
Most of the predictions made for enzyme-substrate recogni-
tion, based on our homology structure of WNV NS3pro, have
been validated by comparing kinetic properties of wild type
with site-specific mutant enzyme variants. The model pre-
dicted the S1 enzyme subsite to be the largest cleft in the
substrate binding groove. This site was investigated in some
detail in this study, and the key interactions implicated were a
-cation interaction between the Tyr-150 and P1 Arg side
chain, a hydrogen bond between the hydroxyl group of Ser-163
and P1 Arg, a salt bridge or strong H-bond between Asp-129
and P1 Arg side chain, and a possible weak hydrogen bond
supplied by Ser-160. Mutations at residue 129 support the idea
that Asp-129 makes an initial interaction with the P1 Arg side
chain before the latter pushes deeper into the S1 pocket where
it binds with Tyr-150 and Ser-163. This could be an important
feature for exploitation in the design of an inhibitor. It is
conceivable that an inhibitor could be designed to interact with
all three residues leading to high affinity.
Only residue Asn-152 was investigated in the S2 subsite of
WNV CF40.Gly.NS3pro. However, this residue was definitively
shown to be crucial for the processing of a substrate with Lys at
P2, a result that implicates an important hydrogen bond be-
tween Asn-152 and the P2 Lys. Further mutagenesis could be
targeted to other residues lining the S2 pocket to search for
additional interactions.
We conclude that residues in both the S1 and S2 subsites of
a recombinant WNV NS3 protease with tethered cofactor were
crucial for substrate processing. These results immediately
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suggest the prospect of designing inhibitors that target both
protease subsites. The dibasic P2/P1 requirement for substrate
recognition is unusual in human serine proteases. Indeed, we
have already shown that conventional serine protease inhibi-
tors do not inhibit WNV CF40.Gly.NS3pro (25). Host cells do
contain some enzymes that process proteins at pairs of basic
residues with often a requirement of a basic residue at P4
and/or P6. Proprotein convertases like furin, for example, rec-
ognize paired basic residues and sometimes have a P6 basic
residue (4). However, basic residues at P4 or P6 are not re-
quired (or desirable) at P4 or P6 in substrates for processing by
WNV NS3 protease. The S2/S1 subsites may therefore repre-
sent ideal targets for design of serine protease inhibitors that
are selective for this and possibly other flavivirus serine pro-
teases over human host serine proteases.
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